XENE
Xenon Pharmaceuticals Inc.Company Information
- Company Name
- Xenon Pharmaceuticals Inc.
- CIK
- CIK0001582313
- Category
- Large accelerated filer
- Ticker: Exchange
- XENE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- XENE
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-08-28
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 122,214
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 94,808,233
- Shares outstanding
- 99,609,804
- Ownership
- 95.18%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -7.06%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 120 | 546 | 199 | 105 | 135 | 117 | 143 | 88 | 137 | 59 | 149 | 100 | ||||||
| Marketable Securities Current | 811 | 549 | 350 | 358 | 352 | 433 | 484 | 566 | 585 | 641 | 489 | 427 | ||||||
| Accounts And Other Receivables Net Current | - | - | - | - | - | 9 | - | - | - | - | - | - | ||||||
| Other Receivables Net Current | 2 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 14 | 11 | 10 | 17 | 12 | 7 | 7 | 5 | 6 | 7 | 6 | 4 | ||||||
| Assets Current | 946 | 1,107 | 561 | 480 | 500 | 566 | 635 | 660 | 728 | 707 | 645 | 531 | ||||||
| Marketable Securities Noncurrent | 314 | 245 | 37 | 93 | 137 | 141 | 127 | 149 | 129 | 186 | 293 | 112 | ||||||
| Operating Lease Right Of Use Asset | 5 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | ||||||
| Property Plant And Equipment Net | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 9 | 10 | 10 | ||||||
| Deferred Income Tax Assets Net | 14 | 12 | 13 | 12 | 11 | 11 | 10 | 1 | 1 | 0 | 1 | 1 | ||||||
| Prepaid Expense Noncurrent | 8 | 8 | 7 | 7 | 9 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
| Assets | 1,296 | 1,387 | 633 | 608 | 674 | 743 | 798 | 836 | 884 | 919 | 965 | 671 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 44 | 38 | 40 | 37 | 32 | 31 | 34 | 28 | 30 | 21 | 26 | 23 | ||||||
| Operating Lease Liability Current | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 45 | 40 | 42 | 38 | 33 | 32 | 36 | 30 | 31 | 22 | 27 | 25 | ||||||
| Operating Lease Liability Noncurrent | 5 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 10 | ||||||
| Other Liabilities Noncurrent | 3 | 3 | 3 | 3 | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities | 53 | 49 | 51 | 48 | 40 | 39 | 43 | 38 | 40 | 31 | 37 | 35 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 2,427 | 2,422 | 1,599 | 1,475 | 1,469 | 1,461 | 1,457 | 1,442 | 1,440 | 1,439 | 1,436 | 1,122 | ||||||
| Additional Paid In Capital Common Stock | 277 | 265 | 228 | 224 | 214 | 208 | 199 | 188 | 177 | 164 | 157 | 138 | ||||||
| Retained Earnings Accumulated Deficit | -1,458 | -1,348 | -1,245 | -1,140 | -1,049 | -965 | -899 | -834 | -771 | -713 | -665 | -620 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -1 | 0 | 0 | 0 | -1 | -2 | 1 | -2 | -2 | -0 | -3 | ||||||
| Stockholders Equity | 1,242 | 1,338 | 582 | 560 | 634 | 704 | 755 | 798 | 844 | 888 | 928 | 637 | ||||||
| Liabilities And Stockholders Equity | 1,296 | 1,387 | 633 | 608 | 674 | 743 | 798 | 836 | 884 | 919 | 965 | 671 | ||||||
| Common Stock Shares Issued | 97 | 97 | 80 | 77 | 77 | 77 | 76 | 76 | 76 | 75 | 75 | 65 | ||||||
| Shares Outstanding | 97 | 97 | 80 | 77 | 77 | 77 | 76 | 76 | 76 | 75 | 75 | 65 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialXenon Pharmaceuticals Inc. (XENE) — SEC Financial Statements & Analysis
Xenon Pharmaceuticals Inc. (XENE) is a pharmaceutical preparations company, incorporated in A1. Xenon Pharmaceuticals Inc. trades on Nasdaq as: XENE. Xenon Pharmaceuticals Inc. (XENE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Xenon Pharmaceuticals Inc. carries a market cap of $6.01B, a P/E ratio of -14.69x, a P/B ratio of 4.84x, a P/S ratio of 473.62x, an enterprise value of $5.89B, and an EV/EBITDA multiple of -13.42x. On profitability, it posts an operating margin of -4974.27%, a net margin of -4612.13%, a Return on Equity (ROE) of -43.62%, a Return on Assets (ROA) of -41.54%, and a Return on Invested Capital (ROIC) of -54.46%. Per share, it reports EPS of $-4.11, diluted EPS of $-4.11, free cash flow per share of $-3.40, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 47.07% year-over-year, and EPS growth of 16.57% year-over-year. On the balance sheet, it maintains a current ratio of 21.02x, a quick ratio of 20.71x, working capital of $900.86M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, free cash flow of $-338.53M (TTM), and net debt of $-119.53M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.01B
- P/E TTM
- -14.69x
- EPS TTM
- $-4.11
- P/B TTM
- 4.84x
- ROE TTM
- -43.62%
- ROA TTM
- -41.54%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-338.53M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Xenon Pharmaceuticals Inc. in?
Xenon Pharmaceuticals Inc. (XENE) operates in the Pharmaceutical Preparations industry.
What exchange does XENE trade on?
Xenon Pharmaceuticals Inc. (XENE) trades on the Nasdaq.
Where is Xenon Pharmaceuticals Inc. incorporated?
Xenon Pharmaceuticals Inc. is incorporated in British Columbia, Canada.
When was Xenon Pharmaceuticals Inc. (XENE)'s most recent SEC filing?
Xenon Pharmaceuticals Inc. (XENE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is XENE's market cap?
Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of $6.01B as of 2026-06-30.
What is XENE's EPS (earnings per share)?
Xenon Pharmaceuticals Inc. (XENE)'s trailing twelve month EPS is $-4.11 as of 2026-06-30.
What is XENE's ROE (return on equity)?
Xenon Pharmaceuticals Inc. (XENE)'s trailing twelve month Return on Equity (ROE) is -43.62% as of 2026-06-30.
What is XENE's ROA (return on assets)?
Xenon Pharmaceuticals Inc. (XENE)'s trailing twelve month Return on Assets (ROA) is -41.54% as of 2026-06-30.
What is XENE's ROIC (return on invested capital)?
Xenon Pharmaceuticals Inc. (XENE)'s trailing twelve month Return on Invested Capital (ROIC) is -54.46% as of 2026-06-30.
What is XENE's EV/EBITDA?
Xenon Pharmaceuticals Inc. (XENE)'s trailing twelve month EV/EBITDA is -13.42x as of 2026-06-30.